Tedopi

Phase 2Small molecule

FFondazione Ricerca Traslazionale

Tedopi is one of 64 small molecule programs targeting Maintenance Therapy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Maintenance TherapyRecruiting

Lung CancerActive, not recruiting

Maintenance TherapyPhase 2

Recruiting

Lung CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

206 competitors in Lung Cancer

#DrugCompanyPhaseTrials

Beyfortus

BeiGene

Phase 3

10 2

Abraxane

Bristol-Myers Squibb

Phase 3

7 3

Alecensa

Roche

Phase 3

3 4

Ilaris

Novartis

Phase 3

2 5

DATROWAY

Daiichi Sankyo

Phase 3

2 6

Verzenio

Eli Lilly

Phase 3

2 7

Lynparza

AstraZeneca

Phase 3

2 8

Zepzelca

Jazz Pharmaceuticals

Phase 3

2 9

Tarlatamab-Dznl

Amgen

Phase 3

2 10

Hycamtin

MMeitheal

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Active, not recruiting

Lung Cancer

NCT04884282

Q4 2029

Phase 2Recruiting

Maintenance Therapy

NCT07264673

Clinical

Trials by Indication[1]

Maintenance Therapy1 trial

A Randomized Phase II Trial of Cemiplimab Plus OSE2101 ( TEDOPI®) as Maintenance Therapy in ctDNA Positive NSCL. The Cemited Study.

Recruiting·FFondazione Ricerca Traslazionale·Phase 2·NCT07264673·160 enrolled

Lung Cancer1 trial

Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)

Active, not recruiting·FFondazione Ricerca Traslazionale·Phase 2·NCT04884282·105 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Tedopi. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tedopi compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tedopi. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fondazione Ricerca Traslazionale company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: FFondazione Ricerca Traslazionale

Tedopi

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q4 2029

Trials by Indication[1]

Maintenance Therapy1 trial

Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News